Kyntra Bio, Inc.Kyntra Bio, Inc.Kyntra Bio, Inc.

Kyntra Bio, Inc.

No trades
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪31.88 M‬USD
40.44USD
‪−47.58 M‬USD
‪29.62 M‬USD
‪3.75 M‬
Beta (1Y)
0.79
Employees (FY)
225
Change (1Y)
−261 −53.70%
Revenue / Employee (1Y)
‪131.65 K‬USD
Net income / Employee (1Y)
‪−680.44 K‬USD

About Kyntra Bio, Inc.


CEO
Thane Wettig
Headquarters
San Francisco
Founded
1993
IPO date
Nov 13, 2014
Identifiers
3
ISIN US31572Q8814
Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

Check out other big names from the same industry as KYNB.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of KYNB is 7.88 USD — it has decreased by −1.62% in the past 24 hours. Watch Kyntra Bio, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Kyntra Bio, Inc. stocks are traded under the ticker KYNB.
KYNB stock has fallen by −12.48% compared to the previous week, the month change is a −9.84% fall, over the last year Kyntra Bio, Inc. has showed a −97.36% decrease.
We've gathered analysts' opinions on Kyntra Bio, Inc. future price: according to them, KYNB price has a max estimate of 43.00 USD and a min estimate of 43.00 USD. Watch KYNB chart and read a more detailed Kyntra Bio, Inc. stock forecast: see what analysts think of Kyntra Bio, Inc. and suggest that you do with its stocks.
KYNB reached its all-time high on Jul 9, 2018 with the price of 42,843.75 USD, and its all-time low was 4.85 USD and was reached on Jun 30, 2025. View more price dynamics on KYNB chart.
See other stocks reaching their highest and lowest prices.
KYNB stock is 8.62% volatile and has beta coefficient of 0.79. Track Kyntra Bio, Inc. stock price on the chart and check out the list of the most volatile stocks — is Kyntra Bio, Inc. there?
Today Kyntra Bio, Inc. has the market capitalization of ‪31.88 M‬, it has decreased by −3.55% over the last week.
Yes, you can track Kyntra Bio, Inc. financials in yearly and quarterly reports right on TradingView.
Kyntra Bio, Inc. is going to release the next earnings report on Mar 2, 2026. Keep track of upcoming events with our Earnings Calendar.
KYNB earnings for the last quarter are 49.61 USD per share, whereas the estimation was −4.01 USD resulting in a ‪1.34 K‬% surprise. The estimated earnings for the next quarter are −3.89 USD per share. See more details about Kyntra Bio, Inc. earnings.
Kyntra Bio, Inc. revenue for the last quarter amounts to ‪1.08 M‬ USD, despite the estimated figure of ‪2.43 M‬ USD. In the next quarter, revenue is expected to reach ‪1.42 M‬ USD.
KYNB net income for the last quarter is ‪148.47 M‬ USD, while the quarter before that showed ‪−7.60 M‬ USD of net income which accounts for ‪2.05 K‬% change. Track more Kyntra Bio, Inc. financial stats to get the full picture.
No, KYNB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 1, 2026, the company has 225 employees. See our rating of the largest employees — is Kyntra Bio, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Kyntra Bio, Inc. EBITDA is ‪−36.97 M‬ USD, and current EBITDA margin is −433.04%. See more stats in Kyntra Bio, Inc. financial statements.
Like other stocks, KYNB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Kyntra Bio, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Kyntra Bio, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Kyntra Bio, Inc. stock shows the sell signal. See more of Kyntra Bio, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.